Chemotherapy Research and Practice / 2012 / Article / Tab 1 / Review Article
CpG Island Methylation, Microsatellite Instability, and BRAF Mutations and Their Clinical Application in the Treatment of Colon Cancer Table 1 Retrospective studies of randomized control trials that examined efficacy of adjuvant 5FU chemotherapy in patients with MSI versus MSS colon cancers.
Reference
No. of patients
Stage
MSI(%) Adjuvant treatment Outcome Better Worse
[9 ]# 570 II/III 17 No treatment MSI MSS 5FU or 5FU/levamisole MSS, more benefit from therapy MSI
[25 ] 542 II/III 18 No treatment MSI = MSS 5FU MSI = MSS
[11 ] 792 III 13 5FU MSI = MSS 5FU + irinotecan MSI, trend for better outcome than 5FU alone MSS
[12 ] 1,327 II/III 14 5FU MSI MSS 5FU + irinotecan No added benefit with irinotecan
[10 ]# 1027 II/III 16 No treatment MSI MSS 5FU or 5FU/levimisole MSS and Stage III—benefit with treatment MSI and stage II-no benefit with treatment
[26 ]# 2141 II/III 16 No treatment MSI MSS 5FU-based therapy
MSI and stage III-benefit with treatment*
5FU = 5FU + leucovorin# Data pooled from overlapping trials.
5FU in addition to: levamisole, portal venous 5FU, interferon-gamma, immunotherapy, vincristine, or semustine.
